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Abstract
Background—Approximately 4.1 million Americans are estimated to have been infected with 
hepatitis C virus (HCV), 45–85% of whom are unaware of their infection. Persons who inject 
drugs (PWID) account for 55.8% of all persons with HCV antibody (anti-HCV) in the U.S. PWID 
have limited access to healthcare and are infrequently tested for anti-HCV using conventional 
laboratory assays.
Objective—To evaluate performance characteristics (sensitivity and specificity) of three, pre-
market rapid point-of-care tests (one oral fluid and two finger-stick assays) from two 
manufacturers (Chembio and MedMira) in settings providing services to young adult PWID in San 
Diego, CA.
Study design—Behavioral risk assessment surveys and testing for HCV were conducted among 
persons who reported injection drug use (IDU) within the past 6 months as part of the Study to 
Assess Hepatitis C Risk (STAHR) among PWID aged 18–40 years in 2009–2010. Sensitivity and 
specificity of the rapid anti-HCV assays were evaluated among STAHR participants, using two 
commonly used testing algorithms.
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Results—Variability in sensitivity (76.6–97.1%) and specificity (99.0–100.0%) was found across 
assays. The highest sensitivity achieved for the Chembio finger-stick blood, Chembio oral fluid 
and MedMira finger-stick blood tests was 97.1%, 85.4% and 80.0% respectively; the highest 
specificity was 99.0%, 100.0% and 100.0%, respectively. In multivariate analysis false negative 
anti-HCV results were associated with female sex for the MedMira blood assay.
Conclusions—Sensitive anti-HCV rapid assays are appropriate and feasible for high-prevalence, 
high-risk populations such as young PWID.
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1. Background
The Centers for Disease Control and Prevention (CDC) estimates that 4.1 million Americans 
have been infected with the hepatitis C virus (HCV) of whom 75–80% are chronically 
infected.3 CDC recommends routine HCV antibody (anti-HCV) testing for persons at risk of 
infection,17 yet recent studies have estimated that 45–85% of HCV-infected persons are 
unaware of their status.21 Knowledge of HCV status is a prerequisite for persons to make 
health-promoting behavior changes and treatment decisions.
Persons with a history of injection drug use (IDU) account for 55.8% of all anti-HCV 
persons in the U.S.26 and CDC estimates that 48% of acute hepatitis C cases in the U.S in 
2007 were attributable to IDU.6 IDU among young adults has been increasing since the 
1990s6 and studies of young persons who inject drugs (PWID) have found anti-HCV 
prevalence of 30–70% among PWID depending on frequency and duration of IDU.2
Many young PWID are unaware of their HCV status,9 although persons who receive drug 
treatment or syringe exchange program services are more likely to be aware than those who 
do not receive these services.7 PWID have limited access to healthcare and are infrequently 
tested for anti-HCV using conventional laboratory assays.24 In addition, results from 
conventional assays are less likely to be received by PWID than are point-of-care (POC) 
results.9 Rapid assays enable specimens to be collected and tested at the POC and do not 
require a follow-up visit to receive antibody test results. Just as rapid HIV testing increases 
the likelihood that PWID receive HIV test results11,13,15,20 and improves access to care and 
health outcomes,10,11 rapid anti-HCV assays could benefit young PWID similarly.
2. Objectives
The purpose of the current study was to assess the performance of three recently developed 
rapid anti-HCV assays that had undergone both a laboratory-based validation18 and a field 
evaluation.19
Jewett et al. Page 2















Data were drawn from the Study To Assess Hepatitis C Risk (STAHR)4 which was 
conducted in San Diego, CA in 2009–2010. STAHR was designed primarily to test three 
recruitment methods of PWID (aged 18–40 years) for the study of hepatitis C. Finger-stick 
blood and oral fluid from consenting participants was tested using rapid anti-HCV assays, 
conventional anti-HCV assays and HCV nucleic acid tests (NAT). Because the rapid tests 
were not approved for diagnostic use by the FDA at the time of data collected, results from 
the conventional anti-HCV and HCV NAT were provided to participants.
3.2. Anti-HCV rapid assays
The Chembio DPP™ HCV test (Chembio Diagnostic Systems, Inc., Medford, NY) and the 
Multiplo™ Rapid HIV/HCV Antibody Test (MedMira Laboratories, Inc., Halifax, Nova 
Scotia, Canada) were evaluated. The two manufacturers responded to a Federal Register 
Notice in 2009 announcing collaboration for the evaluation of rapid HIV and anti-HCV 
assays. The rapid assays are single use, disposable chamber, in vitro, qualitative, immune-
chromatographic assays to detect anti-HCV which provide visual results in less than 40 min. 
More detailed descriptions of each assay can be found elsewhere.18
3.3. Rapid assay performance
The manufacturers provided documentation, instruction manuals, and onsite training for 
performing the assays and interpreting the results. Finger-stick blood and/or oral specimens 
were collected. An assay was interpreted as invalid if the control line was missing or broken, 
as non-reactive if a control line was present (regardless of intensity) with no corresponding 
test line, and reactive with an unbroken control and test line.
3.4. Reference assays
All specimens in the evaluation panel were tested for anti-HCV by the AxSYM anti-HCV 
Microparticle Enzyme Immunoassay (Abbott Laboratories, Abbott Park, IL) (MEIA). A 
third generation recombinant immunoblot assay (RIBA: The Chiron RIBA HCV 3.0 SIA; 
Novartis Vaccines & Diagnostics, Inc., Emeryville, CA) was used to confirm antibody 
positivity for reactive specimens with a signal to cut off (s/co) ratio below the CDC-
recommended threshold and has the effect of increasing the sensitivity.1 Nucleic acid testing 
(NAT) was conducted on all specimens in the evaluation panel to test for viremia (see 
Technical Appendix).
3.5. Specimen panel
PWID were recruited from a syringe exchange program, a community-based organization 
focused on HIV prevention, and the broader community via targeted outreach. A total of 409 
specimens were obtained (114 anti-HCV positive, 295 anti-HCV negative) and tested by the 
three assays: the Chembio blood assay, the Chembio oral assay and the MedMira blood 
assay.
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Performance of each anti-HCV rapid assay was evaluated in comparison to the results from 
the two conventional reference methods most commonly used in public laboratories.26 
Sensitivity and specificity were assessed by comparing the results of the rapid assays first to 
the results of the MEIA only (screening assay [SA] reference method) and second, to the 
results of the CDC-recommended HCV testing algorithm (CDC reference method)1 (see 
Technical Appendix).
3.7. Sensitivity and specificity
Sensitivity was defined as the number of positive specimens detected by the rapid assay 
divided by the total number of reference assay positive specimens. Specificity was defined 
as the number of negative specimens identified by the rapid assay divided by the total 
number of the reference assay negative specimens. Confidence intervals for sensitivity and 
specificity were calculated using the Wilson Score method.23,27 Multivariate logistic 
regression was used to determine whether discordant rapid anti-HCV results, conventional 
anti-HCV results, RIBA results and HCV NAT results were predicted by selected 
demographic variables (sex, age, race/ethnicity, injection duration and HIV RNA status) 
using both reference methods. Data analysis was performed using PASW 18.0 (Chicago, IL).
4. Results
Of 566 STAHR participants, 409 (72.3%) provided informed consent and completed rapid 
testing for this sub-study; 15 persons refused the rapid test. Invalid rapid assay results 
[Chembio blood (n = 2), Chembio oral (n = 7) and MedMira (n = 33)] occurred for all three 
assays resulting in a smaller analytic sample. On average, participants were aged 29.2 years 
(range aged 18–40 years; standard deviation = 6.2), and the majority were White (51.1%) or 
Hispanic (29.3%) and male (74.1%) (Table 1).
Compared to the SA method, the sensitivity for the Chembio blood assay was 92.8% and 
specificity was 99.0%; sensitivity for the Chembio oral fluid assay was 81.8% and 
specificity was 100.0%; and sensitivity for the MedMira blood assay was 76.6% and 
specificity was 100.0%. Sensitivities increased using the CDC reference method across 
assays, although not significantly (Table 2).
Discordant results were analyzed to determine if an association existed for selected 
demographics. False negative rapid anti-HCV results were associated with female sex for the 
MedMira blood assay (aOR = 3.07; 95% CI, 1.12–8.39; p = 0.03) using the CDC reference 
method. Discordant results also were compared to HCV NAT results. Of the 409 specimens, 
two (0.49%) were HCV NAT positive but anti-HCV negative and rapid anti-HCV negative 
by all three rapid assays. Twenty-five (6.1%) specimens were SA anti-HCV positive and 
HCV NAT negative (Table 3). Five of the 25 specimens with low s/co ratios were identified 
as negative by RIBA and also identified as rapid anti-HCV negative by all three assays.
Of the 11 RIBAs that were conducted, two were indeterminate and therefore excluded from 
the CDC reference analysis. The indeterminate specimens were both HIV-positive and the 
rapid assays identified the specimens as anti-HCV positive. Of the 15 total HIV-positive 
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specimens, 7 (46.7%) were SA anti-HCV positive and 5 (33.3%) were CDC anti-HCV 
positive. All three rapid tests concurred with the SA method positive results. Chembio blood 
had one false positive among the HIV mono-infected specimens.
5. Discussion
This field evaluation of three pre-market rapid assays found considerable variability in 
sensitivity across assays. Sensitivity ranged from 76.6% to 97.1%, which is similar to the 
findings of previous studies (sensitivity 78.9–97.8%).18,19 Sensitivities of the Chembio oral 
fluid and MedMira blood assays were similar, while the sensitivity of the Chembio blood 
assay was significantly higher than the MedMira blood assay. The Chembio and MedMira 
assays specificity ranged from 99.0% to 100.0%, which is higher than in previous studies 
(80.0–99.8%).18,19
These results are similar to the findings of recent CDC laboratory18 and field19 evaluations 
of POC assays, although as might be expected, sensitivity in field use was slightly lower 
than in laboratory use. These differences in rapid assay sensitivity between laboratory and 
field settings are similar to those found for HIV rapid assays.5,16 These differences may be 
due to the use of recently collected whole blood in the field versus stored serum in the 
laboratory, differences in technical expertise of those performing the assays, and possible 
contamination in field settings versus a more sterile laboratory setting.
Comparing sensitivities and specificities of rapid assays requires operational and 
interpretable assays. In this study, as well as in previous studies, MedMira had more invalid 
rapid assay results than Chembio oral and blood combined (9% versus <2%, respectively), 
resulting in lower utility of the assay. Anecdotal reports from testers suggested that the 
MedMira assay was more difficult to perform and interpret than the Chembio assays.
As expected, using the CDC reference method resulted in somewhat higher sensitivity for all 
assays than using the SA reference method. Two of the eleven (18%) RIBA results in this 
study were indeterminate, which is similar to a laboratory evaluation and a field study 
conducted by CDC where two of 10 (20%)18 and 4 of 25 (16%) RIBA results,19 respectively 
were indeterminate. One of the RIBA indeterminate results was rapid test reactive and NAT 
positive. The other RIBA indeterminate result was rapid test reactive and NAT negative.
The HIV prevalence of 3.7% (n = 15) among all rapid assay evaluation participants was 
similar to that found among PWID in previous studies.25 HIV-HCV co-infection was low 
(ranging from 30.7% to 33.3% among persons with HIV across reference methods) in this 
sample as compared with other PWID studies (80–89%).7,21,22 Some of this may be 
attributable to age as anti-HCV is less prevalent among younger populations, resulting in 
lower co-infection rates.21
Discordant results (SA positive and NAT negative (N = 25)) could be spontaneous clearers, 
however follow-up testing would be required to confirm. Female sex was a significant 
predictor of false negative anti-HCV rapid test results for the MedMira assay using the CDC 
reference method but not for the other assays. The association of false results identified in 
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this study was different from the associations found in other field settings (HIV and race/
ethnicity).19 Studies with larger sample sizes would be needed for further analysis.
Using anti-HCV rapid assays, PWID would receive their results at the POC on the same day, 
increasing the likelihood that they could be provided with prevention counseling messages 
and referrals for follow up. In this study, only 53.3% of persons tested in this study received 
their conventional anti-HCV test results and on average received them 27.5 days after 
testing, results which are comparable to those seen in other studies.8 Rapid anti-HCV assays 
which utilize oral fluid or capillary blood have the benefit of not requiring a phlebotomist 
and can be provided at POC, expanding testing options for PWID.12,14 Rapid anti-HCV 
assays could be administered in syringe exchange programs (both through store fronts and 
mobile units), methadone maintenance treatment programs, and other programs that provide 
direct services to persons who inject drugs.
6. Conclusion
We found further evidence that sensitive rapid anti-HCV assays can be useful for the 
detection of anti-HCV among persons at risk for HCV, such as PWID who can be reached 
through specific social service settings, such as syringe exchange programs. Of the three 
assays evaluated, the Chembio blood rapid assay demonstrated acceptable sensitivity and 
specificity, and was comparable to conventional assays currently in use.
While this study is not generalizable beyond our study population, some limitations from 
previous studies were addressed. For example, in the previous field study19 testing one 
specimen with multiple rapid assays and NAT was not feasible and in the laboratory study18 
the rapid assays were not tested in the field, while in this study we were able to gather and 
analyze such data, enabling direct comparison of assay performance in the field where rapid 
assays would most likely be utilized.
Rapid anti-HCV tests will require further evaluation. Demonstration projects should be 
conducted to evaluate the impact of integrating rapid anti-HCV testing into protocols used at 
HIV testing sites. CDC should evaluate the HCV testing algorithm given that the RIBA 
confirmatory test is expensive and added limited information regarding antibody status. 
Finally, standardized educational materials and guidance for post-test counseling for anti-
HCV rapid assay positive persons need to be developed and evaluated.
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